Of note, APL is a subtype of AML, characterized by the presence of the promyelocytic leukemia-retinoic acid receptor α (PML/RARα) fusion protein, which induces an oncogenic transcriptional silencing of the Retinoic Acid (RA) signaling pathway and causes the block of differentiation at the promyelocytic stage and neoplastic transformation of APL blasts (Grignani et al., 1998; Di Croce et al., 2002). The gene discussed is RARA; the disease is acute myeloid leukemia.